RegeneRx Biopharmaceuticals, Inc. (RGRX)

Market Cap	453.00 -100.0%
Revenue (ttm)	76.76K -0.0%
Net Income	-1.69M
EPS	-1.18
Shares Out	1.51M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	550
Average Volume	2,131
Open	0.0003
Previous Close	0.0003
Day's Range	0.0003 - 0.0003
52-Week Range	0.0002 - 0.1630
Beta	179.89
RSI	46.73
Earnings Date	n/a

About RGRX

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, develops pharmaceuticals from Thymosin beta 4 (Tβ4) for tissue protection, repair, and regeneration. The company is developing RGN-259, a sterile and preservative-free eye drop that has completed Phase 3 clinical trial for the treatment of dry eye syndrome and neurotrophic keratitis. It has strategic partnerships with Lee’s Pharmaceutical Group for the development and marketing of Tβ4-related products; and HLB Therapeutics for the development and marketing of RGN-259, and RGN-137 f...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1982
• Employees: 3
• Stock Exchange: OTCMKTS
• Ticker Symbol: RGRX

Financial Performance

In 2022, RGRX's revenue was $76,761, a change of 0.00% compared to the previous year's $76,761. Losses were -$1.73 million, 8.12% more than in 2021.